Dixon Technologies Vivo JV: What Approval Means in FY27

Why the Vivo joint venture is back in focus

Dixon Technologies is back in the spotlight after reports suggested the government is likely to approve its proposed joint venture (JV) with Vivo India. The deal has been closely tracked because it could materially expand Dixon’s smartphone manufacturing scale and improve revenue visibility for several years. Market participants have also linked the JV approval to a potential re-rating for domestic electronics manufacturing services (EMS) companies, as long-term order visibility typically supports higher valuation multiples.

The renewed interest followed brokerage updates that framed the JV as a key near-term catalyst for Dixon’s earnings outlook. While formal government approval is still pending, the narrative in the market has shifted toward a higher probability of clearance. Dixon has also clarified that the term sheet remains pending approvals, with no new developments disclosed.

Deal structure: stakes and the Noida plant

Dixon and Vivo signed an agreement in December 2024 to set up a JV in which Dixon will hold a 51% stake and Vivo India will hold 49%. Under the proposed structure, Vivo’s manufacturing facility in Noida is expected to become part of the JV.

For Vivo, the arrangement is widely seen as a way to reduce regulatory and operational risk exposure in India by embedding manufacturing within a domestic partner-led structure. For Dixon, the deal represents a chance to add large volumes from one of India’s highest-volume smartphone brands and deepen its position in mobile EMS.

What JM Financial changed: upgrade and higher target

JM Financial Institutional Securities upgraded Dixon Technologies to ‘Buy’ from ‘Add’ and raised its target price by 27% to ₹14,200 from ₹11,200. The brokerage said there is no longer a need to downgrade earnings per share estimates, as it expects the JV’s earnings to start contributing to Dixon’s profit and loss statement by the end of the September quarter.

JM Financial’s upgrade was driven by improved visibility on the Vivo JV, expectations of higher average smartphone selling prices, and steady progress in Dixon’s IT hardware business. The brokerage noted Dixon’s IT hardware client roster includes HP, Lenovo, Acer and Asus.

Scale opportunity: how many Vivo phones could shift to Dixon

JM Financial estimates that nearly two thirds of Vivo’s annual India volumes of 35 to 37 million smartphones could eventually be manufactured through the JV. That implies roughly 22 to 24 million units of additional annual production opportunity for Dixon, once the partnership stabilises.

The brokerage also noted that the remaining Vivo volumes are manufactured by Bhagwati Products through its original design manufacturer Huaqin. JM Financial said the full impact of the JV opportunity is expected to be witnessed in FY28 (2027-28).

When production could start, and when financials may reflect it

On timelines, JM Financial expects commercial production under the Vivo JV to begin roughly two months after final regulatory approval is received. Separately, commentary in the provided updates also pointed to operations starting after 60 to 90 days, once approval comes through.

JM Financial expects JV earnings to start contributing to Dixon’s reported numbers by the end of the September quarter, and noted that the deal could support improved revenue visibility through FY28. The expectation of earlier contribution is one reason brokerages see the approval as a major overhang.

Guidance and operating metrics cited in the updates

The updates cited several operating and market-share datapoints for context. Vivo’s share of total smartphone volumes in India was stated at 19.2% in FY26, with projections rising to 24.3% in FY27 and 34% in FY28.

The same set of notes said exports, supported by production-led incentives, increase the scope for Dixon achieving guidance of producing 63 to 65 million smartphones in FY28 and 68 to 72 million in FY29. JM Financial also said Dixon is on track for smartphone volume guidance of around 33 million in FY27 excluding Vivo. For the June quarter, the note cited smartphone volumes of around 7.5 million and revenue of about INR 95 million (₹9.5 crore after unit normalisation) on higher average selling prices.

Stock move and what the market is pricing

Dixon Technologies shares were cited trading at ₹12,201 on NSE, up about 0.95% from the previous close of ₹12,086, and touching an intraday high of ₹12,284. The move followed JM Financial’s upgrade and the higher target price.

A separate market comment in the provided text framed a “fair value” trading range of ₹12,000 to ₹12,500 in the absence of Vivo approval. The same comment suggested that if approval comes in FY27 and Dixon captures some volume during FY27, a 10% to 15% earnings upgrade could be seen, although this was presented as a scenario rather than a confirmed outcome.

What JPMorgan is saying: Overweight stays, but approval is key

JPMorgan maintained an Overweight rating on Dixon Technologies with an unchanged target price of ₹12,700, while highlighting the scale opportunity from shifting a large share of Vivo’s India manufacturing into the JV structure. The brokerage linked the move to the broader Make in India push.

In its note, JPMorgan also argued that approval could “nullify the notion” that the development is already priced in. It expects the JV could contribute 11 million units to mobile volumes in FY27 and 22 million units in FY28, potentially driving a 24% to 39% upgrade to revenue estimates during this period and a 13% to 18% EPS upgrade, taking fair value to ₹15,100 (as cited in the updates). It also flagged two near-term catalysts: JV approval and a potential PLI 2.0 scheme announcement.

Sector implications: why this could affect EMS valuations

The provided market view described the sector impact as a likely re-rating of domestic EMS multiples due to improved revenue visibility. That logic rests on the idea that long-duration manufacturing programs, once approved and ramped, reduce uncertainty around utilisation and cash flows. The updates also said Dixon management indicated the Vivo deal could represent a revenue opportunity of ₹30,000 crore.

Beyond the Vivo JV, the same text pointed to Dixon’s backward integration push, including component manufacturing for sub-assemblies and printed circuit boards. The stated rationale is to reduce dependence on imported components, protect margins as PLI incentives taper, and comply with rising domestic value-addition requirements.

Key facts at a glance

What to watch next

The single most important near-term trigger remains regulatory approval for the Vivo JV. Brokerages that are constructive on the stock have tied their optimism to how quickly production ramps after approval and how much of Vivo’s India volume moves into the JV.

Investors will also track commentary on timelines for commercial production, any disclosures around incorporating the Noida facility into the JV, and how Dixon’s non-smartphone segments, including IT hardware and telecom equipment, progress alongside the mobile ramp.